abrdn Life Sciences Investors (NYSE:HQL) Shares Bought by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC grew its holdings in shares of abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 16.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 193,484 shares of the company's stock after purchasing an additional 27,433 shares during the period. Allspring Global Investments Holdings LLC owned approximately 0.67% of abrdn Life Sciences Investors worth $2,455,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Steward Partners Investment Advisory LLC boosted its stake in shares of abrdn Life Sciences Investors by 379.8% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,860 shares of the company's stock worth $64,000 after acquiring an additional 3,847 shares in the last quarter. Wealthcare Advisory Partners LLC purchased a new stake in abrdn Life Sciences Investors in the 1st quarter valued at approximately $131,000. Cambridge Investment Research Advisors Inc. purchased a new stake in abrdn Life Sciences Investors in the 1st quarter valued at approximately $134,000. Landscape Capital Management L.L.C. purchased a new position in shares of abrdn Life Sciences Investors during the 4th quarter worth $154,000. Finally, Guggenheim Capital LLC purchased a new position in shares of abrdn Life Sciences Investors during the 4th quarter worth $211,000. Institutional investors and hedge funds own 32.21% of the company's stock.

Insider Transactions at abrdn Life Sciences Investors

In other abrdn Life Sciences Investors news, major shareholder Saba Capital Management, L.P. sold 11,419 shares of the business's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $12.71, for a total transaction of $145,135.49. Following the completion of the sale, the insider owned 3,017,539 shares of the company's stock, valued at approximately $38,352,920.69. The trade was a 0.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 92,544 shares of company stock worth $1,087,994 over the last ninety days. 10.06% of the stock is currently owned by insiders.

abrdn Life Sciences Investors Price Performance

Shares of abrdn Life Sciences Investors stock opened at $13.09 on Monday. abrdn Life Sciences Investors has a fifty-two week low of $10.55 and a fifty-two week high of $15.90. The business's fifty day moving average is $12.58 and its two-hundred day moving average is $12.93.

abrdn Life Sciences Investors Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, June 30th. Investors of record on Thursday, May 22nd were issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 13.14%. The ex-dividend date was Thursday, May 22nd.

About abrdn Life Sciences Investors

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.